Metastatic invasive lobular breast cancer with stomach, ovarian, peritoneal, rectal, and jejunal spread

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Primary tumor and gastric metastasis were ER/PR positive and HER2 negative; GATA3 supported breast origin in the metastasis.

Metastatic Site: stomach; ovaries; peritoneum; rectum; jejunum

During 2025, she remained under active oncologic management for metastatic invasive lobular breast cancer with gastrointestinal, ovarian, peritoneal, rectal, and jejunal involvement.

PubMed CentralRead more →

Triple-Negative Breast Cancer: Jacqueline's Patient Story

Patient Info: Jacqueline Bennett, Female, Under 40

Biomarkers: Initial ER-negative, PR-negative, HER2-negative; later HER2-positive

Jacqueline completed treatment for initial Stage IA triple-negative breast cancer during pregnancy and later developed a HER2-positive, hormone receptor-negative breast cancer. After 3 of 6 current treatments, the tumor was no longer visible on ultrasound or MRI, with targeted therapy and double mastectomy still planned.

The Patient StoryRead more →

Triple-negative breast cancer diagnosed during pregnancy: remission

Patient Info: Anonymized, Female, Under 40

Biomarkers: ER-negative; PR-negative; HER2-negative

The patient remains in remission 30 months after surgery. Immune-related brachial plexopathy after treatment improved after steroids, IVIG, and plasmapheresis, with electrophysiologic resolution and near-complete strength and sensory recovery.

PubMed CentralRead more →

Non-metastatic metaplastic triple-negative breast cancer with residual disease after chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Metaplastic triple-negative breast cancer; HER2 0

The patient had an initial partial response to neoadjuvant chemotherapy but then progressed before surgery. Modified radical mastectomy found substantial residual metaplastic carcinoma with 0/21 nodes involved, followed by adjuvant radiotherapy and metronomic capecitabine.

PubMed CentralRead more →

Stage III HER2-Positive Breast Cancer: Caroline's Patient Story

Patient Info: Caroline McNally, Female, Under 40 | Stage III

Biomarkers: Hormone-positive component reported; exact ER/PR/HER2 panel not stated

As of February 2026, Caroline was in active treatment for Stage III hormone-positive breast cancer, receiving Taxol after dose-dense AC and preparing for double mastectomy, likely radiation, and hormone therapy.

Stage IIIB triple-negative metaplastic breast cancer: urgent mastectomy and reconstruction after rapid progression on neoadjuvant therapy

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; nuclear grade 3

At 18-month follow-up, she was disease-free after urgent mastectomy, axillary dissection, flap/skin-graft reconstruction, resumed chemotherapy, and radiation for rapidly progressive triple-negative metaplastic breast cancer.

PubMed CentralRead more →

Metastatic triple-negative breast cancer with sacituzumab-govitecan pneumonitis and progression

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: lung

Sacituzumab-govitecan pneumonitis improved with corticosteroids and half-dose rechallenge did not reproduce pneumonitis, but follow-up CT showed one new pulmonary metastasis and enlargement of previous lung metastases; PFS on sacituzumab govitecan was 5.37 months.

PubMed CentralRead more →

Stage III Breast Cancer Treatment Complicated by Coronary Thrombosis

Patient Info: Anonymized, female, 40s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative; Ki-67 25–30%

She achieved complete remission about 12 months after the myocardial infarction and remained in complete oncologic remission at 44 months.

PubMed CentralRead more →

Metastatic breast cancer history with pacing-induced cardiomyopathy and heart-function recovery

Patient Info: Anonymized, Female, 50s | Stage IV

Metastatic Site: sternum; ribs

She had osseous metastatic breast cancer involving the sternum and ribs, while pacing-induced cardiomyopathy improved clinically and biventricular function recovered completely at 6 months on medical therapy.

PubMed CentralRead more →

Stage IV Breast Cancer: Lea's Patient Story

Patient Info: Lea, Female, Under 40 | Stage IV

Metastatic Site: Bone: hip sockets, femurs, spine; liver

As of January 2026, Lea was living with metastatic breast cancer involving bone and liver and was in active treatment with Taxol after progression changed her treatment plan.

Stage 3 triple-negative breast cancer complicated by immunotherapy endocrine toxicity

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PgR-negative/PR-negative; HER2 0; Ki-67 70%; triple-negative breast cancer

After neoadjuvant therapy complicated by immune-related hypothyroidism, adrenal insufficiency, and suspected hypophysitis, surgery showed residual ypT1c ypN0 triple-negative disease. Pembrolizumab was stopped, adjuvant capecitabine was completed in June 2025, and endocrine replacement/follow-up continued.

PubMed CentralRead more →

Hormone receptor-positive breast cancer treated with pembrolizumab trial complicated by acquired lipodystrophy

Patient Info: Anonymized, Female, 40s

Biomarkers: HER2-negative breast cancer. Metabolic changes occurred during/after pembrolizumab.

As of December 2025, breast cancer treatment had included neoadjuvant chemotherapy/pembrolizumab, surgery, adjuvant pembrolizumab, and endocrine therapy; CT did not show recurrence during weight-loss evaluation, but she required ongoing metabolic care for pembrolizumab-associated acquired generalized lipodystrophy.

PubMed CentralRead more →

Metastatic Breast Cancer Causing Bile Duct Obstruction and Liver Failure

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: Metastatic biopsy ER-negative, PR-negative, HER2-negative

Metastatic Site: bone, liver, common bile duct

Her metastatic breast cancer progressed rapidly with diffuse liver involvement and bile-duct invasion, leading to liver failure and death 28 days after admission.

PubMed CentralRead more →

Glycogen-rich clear cell breast carcinoma: HER2-positive early-stage case with disease-free follow-up

Patient Info: Anonymized, Female, 60s | Stage I

Biomarkers: ER-positive; HER2-positive; PR-negative; Ki-67 ~10%; intracytoplasmic glycogen confirmed

At 1-year follow-up, she had no evidence of breast cancer recurrence.

PubMed CentralRead more →

I Was Told I Was TOO YOUNG For Breast Cancer!

Patient Info: Anonymized, Female | Stage IV

Metastatic Site: mediastinum; lymph nodes between the lungs

As of November 2025, the patient was living with Stage IV metastatic breast cancer, described as lifelong and requiring ongoing treatment. She had also completed local treatment for a later breast lesion.

YouTube — The Patient StoryRead more →

Stage I AR-positive triple-negative invasive apocrine breast carcinoma: disease-free after surgery, radiotherapy and chemotherapy

Patient Info: Anonymized, Female, 50s | Stage I

Biomarkers: Triple-negative apocrine breast carcinoma with androgen receptor 90%

At 1-year follow-up, she remained disease-free with no clinical or radiologic evidence of recurrence.

PubMed CentralRead more →

Triple-negative breast cancer with pathologic complete response after neoadjuvant chemoimmunotherapy complicated by immune toxicity

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative

Left mastectomy on November 17 confirmed pathologic complete response, and 5-month follow-up showed no residual hepatic, dermatological, metabolic, or neurological sequelae from the treatment-related complications.

PubMed CentralRead more →

Recurrent breast cancer complicated by T-DXd-associated dermatomyositis and interstitial lung disease

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Initial tumor had weak ER/AR, PR-negative, HER2 0. Recurrence became ER/PR/AR-negative, HER2-low, PD-L1 CPS ~30.

The cancer progressed after adjuvant therapy and again after 6 cycles of gemcitabine/carboplatin. Trastuzumab deruxtecan was followed by dermatomyositis features and interstitial pneumonia, with symptoms worsening despite glucocorticoid treatment after continued exposure.

PubMed CentralRead more →

HER2-positive breast cancer: brain recurrence, T-DXd liver injury, and later progression

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2-positive; hormone receptor-negative; grade 3 infiltrative breast carcinoma

Metastatic Site: brain; thoracic lymph nodes

As of October 2025, the patient had developed brain and thoracic nodal recurrence after HER2-directed treatment, experienced T-DXd-associated liver injury, progressed after later paclitaxel/trastuzumab, and died at home in December 2024 under palliative care.

PubMed CentralRead more →

Stage IIIB HER2-positive breast cancer followed by resected pancreatic ductal adenocarcinoma

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: Breast cancer HER2-amplified; ER/PR changed from positive to negative after treatment. Pancreatic markers supported a separate pancreatic cancer.

The breast cancer achieved radiological and clinical remission after multimodality HER2-directed treatment. In 2025, a separate pancreatic ductal adenocarcinoma was resected, and adjuvant gemcitabine plus albumin-bound paclitaxel was recommended.

PubMed CentralRead more →

Stage IIIC ER-positive male breast cancer: mastectomy, chemotherapy, radiation, tamoxifen and abemaciclib

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: ER 90% positive; PR 60% positive; HER2 score 0; Ki-67 15%; BRCA1 and BRCA2 no pathogenic variants; CEA 2.4 ng/mL; CA15-3 13.6 U/mL

He remained on tamoxifen and dose-adjusted abemaciclib; annual follow-up imaging, including non-contrast CT, showed no local or distant relapse.

PubMed CentralRead more →

HER2-positive luminal B breast cancer with axillary tumor deposits: no recurrence after multimodal therapy

Patient Info: Anonymized, Female, 50s

Biomarkers: HER2-positive

After neoadjuvant therapy, mastectomy, axillary dissection, continued hormone therapy, and trastuzumab, she remained in good clinical condition with no detected recurrence.

PubMed CentralRead more →

Stage IIA male breast cancer: chemotherapy, mastectomy, endocrine therapy, and benign adrenal nodule

Patient Info: Anonymized, Male, 50s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-negative

Final breast cancer pathology was T1N1M0 / AJCC Stage IIA ER-positive, PR-positive, HER2-negative invasive ductal carcinoma; the suspicious adrenal lesion was removed in June 2025 and proved to be a benign adrenal adenoma.

PubMed CentralRead more →

Triple-negative breast cancer history with later chest wall sarcomatoid carcinoma treated by embolization, ablation, and chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Initial breast cancer was triple-negative. Later chest-wall lesion was weak ER-positive, PR/HER2-negative

By February 2025, the treated chest wall lesion had decreased to about 13 x 7 mm after embolization, radiofrequency ablation, and albumin-bound paclitaxel plus cisplatin, with no peripheral or distant metastatic foci seen.

PubMed CentralRead more →